-
平臺(tái)編號(hào)：bio-68299
-
國(guó)際編號(hào)：CRL-2327?
-
細(xì)胞信息： HCC1428
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
HCC1428
細(xì)胞形態(tài)：上皮樣
ATCC Number：CRL-2327?
相關(guān)疾?。合侔?br /> 數(shù)量：大量
年限：TNM stage IV, grade 4
運(yùn)輸方式：凍存運(yùn)輸
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
是否是腫瘤細(xì)胞：0
物種來(lái)源：人
器官來(lái)源：乳房
規(guī)格：48T Designations: HCC1428
Depositors: ?AF Gazdar, AK Virmani
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent; large epithelial cells with occasional vacuole formation
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: mammary gland; breast
Tumor Stage: TNM stage IV, grade 4
Disease: adenocarcinoma
Derived from metastatic site: adenocarcinoma and pleural effusion
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Isolation: Isolation date: November 4, 1995
Applications:The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers.
Oncogene:her2/neu -, p53 -
DNA Profile (STR):CSF1PO: 10
D13S317: 12
D16S539: 12,8
D5S818: 11,12
D7S820: 9
THO1: 8
TPOX: 8
vWA: 17
Cytogenetic Analysis:polyploid
Age: 49 years
Gender: female
Ethnicity: Caucasian, White
Comments:This cell line was initiated on 11/4/95 and took 15 months to establish.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers.
There is a familial history of breast cancer (maternal grandmother).
The cells are negative for expression of Her2-neu and for expression of p53.
HCC1937 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19.
An EBV transformed lymphoblastoid cell line [HCC1428 BL] from the same patient is available as ATCC CRL-2328. The homozygous deletion in the FHIT gene is retained in the lymphoblastoid line.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derived from same individual:ATCC CRL-2328
References: 32258: Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768
38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
ATCC Number：CRL-2327?
相關(guān)疾?。合侔?br /> 數(shù)量：大量
年限：TNM stage IV, grade 4
運(yùn)輸方式：凍存運(yùn)輸
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
是否是腫瘤細(xì)胞：0
物種來(lái)源：人
器官來(lái)源：乳房
規(guī)格：48T Designations: HCC1428
Depositors: ?AF Gazdar, AK Virmani
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent; large epithelial cells with occasional vacuole formation
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: mammary gland; breast
Tumor Stage: TNM stage IV, grade 4
Disease: adenocarcinoma
Derived from metastatic site: adenocarcinoma and pleural effusion
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Isolation: Isolation date: November 4, 1995
Applications:The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers.
Oncogene:her2/neu -, p53 -
DNA Profile (STR):CSF1PO: 10
D13S317: 12
D16S539: 12,8
D5S818: 11,12
D7S820: 9
THO1: 8
TPOX: 8
vWA: 17
Cytogenetic Analysis:polyploid
Age: 49 years
Gender: female
Ethnicity: Caucasian, White
Comments:This cell line was initiated on 11/4/95 and took 15 months to establish.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers.
There is a familial history of breast cancer (maternal grandmother).
The cells are negative for expression of Her2-neu and for expression of p53.
HCC1937 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19.
An EBV transformed lymphoblastoid cell line [HCC1428 BL] from the same patient is available as ATCC CRL-2328. The homozygous deletion in the FHIT gene is retained in the lymphoblastoid line.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Protocol:
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derived from same individual:ATCC CRL-2328
References: 32258: Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768
38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
